Interestingly, the pathological environment in the CSF of PD patients promotes the same modifications in the exogenously added ceruloplasmin, with the consequent loss of ferroxidase activity and gain of integrin binding properties, which in turn rise warnings about a potential therapeutic use of ceruloplasmin in patients. Here, CP is linked to Parkinson disease.